Trial Profile
A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX-COMBO): Immunogenicity, Carriage and Otitis Media Outcomes.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Otitis media; Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms PREV-IX; PREV-IX-COMBO; PREVIX_COMBO
- 01 Sep 2022 Results (n=261; Between April 10, 2013, and Sept 4, 2018) assessing the immunogenicity of novel pneumococcal conjugate vaccine (PCV) schedules from PREVIX_COMBO and PREVIX_BOOST randomised controlled trials, published in The Lancet Infectious Diseases.
- 23 Mar 2021 Primary endpoint of he proportion of nasopharyngeal (Np) swabs positive for PCV13 at 7 months has not been met, according to results published in the Vaccine.
- 23 Mar 2021 Results published in the Vaccine